Table 1.
Animal | rIL-15 | Dose | Route | Frequency | Immunological Effect | Toxicity | Reference |
---|---|---|---|---|---|---|---|
rhesus | E. coli derived Rhesus, | 10 μg/kg | S.Q. | Daily, 1×/wk for 6 weeks | Increased CD4 T cells | No adverse events | [90] |
cyno | E. coli derived Rhesus, | 10, 100 μg/kg | S.Q. | 2×/wk for 4 weeks | Increase CD8 and CD4 Tem, NK cells | None reported | [91] |
rhesus | E. coli derived Rhesus, | 10 μg/kg | Not stated | Day 1,2,or day 1,3,7 | Increase CD8 CD4 Tem | None reported | [41] |
rhesus | E. coli derived human | 20 μg/kg/day | Continuous I.V. | 10 days | 100× CD8 Tem 10× NK |
Moderate Increase AST/ALT, neutropenia | [39] |
20–40 μg/kg | S.Q. | Daily | 10× CD8 Tem 10× NK |
Mild Increase AST/ALT, | |||
rhesus | E. coli derived human | 10, 20,50 μg/kg | I.V. | Daily for 12 days | 4× CD8 Tcm, 6× CD8 Tem, 2.5× CD4 T cells, 6× NK cells | Neutropenia, weight loss, decrease appetite, diarrhea, | [33,40] |
rhesus | Mammalian-derived human | 15 μg/kg | S.Q. | Daily for 14 days | Increase CD8 and CD4 Tm, NK cells | Severe neutropenia, anemia, weight loss, rash | [34] |
2.5–10 μg/kg | S.Q. | Every 3 days for 24 days | Increase CD8 and CD4 Tm, NK cells | Well tolerated |